CytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conf...
October 16 2017 - 1:00PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced that preclinical results will
be presented at the 2017 AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics. The conference will take
place October 26-30 in Philadelphia.
Abstract Information:
Title: |
EGFR-CD3 bispecific Probody therapeutic induces tumor regressions
and increases maximum tolerated dose >60 fold in preclinical
studies |
Session Category: |
EGFR/Her2 |
Date: |
Saturday, October 28 |
Time: |
Poster Session A: 12:30 p.m. – 4:00 p.m. |
Location: |
Hall E, Pennsylvania Convention Center |
Abstract: |
A164 |
The EGFR-CD3 bispecific Probody therapeutic poster will also be
included in the Spotlight on Proffered Papers session starting at
10:50 a.m. on Friday, October 27 in the Terrance Ballroom, 400
level.
Title: |
Optimizing a CD71-targeting Probody drug conjugate (PDC) for
activity in multiple solid tumor and lymphoma models and for
tolerability in nonhuman primates |
Session Category: |
Therapeutic Agents: Biological |
Date: |
Sunday, October 29 |
Time: |
Poster Session B: 12:30 p.m. – 4:00 p.m. |
Location: |
Hall E, Pennsylvania Convention Center |
Abstract: |
B116 |
Title: |
A multi-analyte HPLC-MS/MS approach to assessing exposure of a
Probody drug conjugate (PDC) in preclinical studies |
Session Category: |
Therapeutic Agents: Biological |
Date: |
Sunday, October 29 |
Time: |
Poster Session B: 12:30 p.m. – 4:00 p.m. |
Location: |
Hall E, Pennsylvania Convention Center |
Abstract: |
B103 |
Title: |
Nonclinical safety evaluation of two distinct second generation
variants of anti-CTLA4 monoclonal antibody, ipilimumab, in
monkeys |
Session Category: |
Therapeutic Agents: Biological |
Date: |
Sunday, October 29 |
Time: |
Poster Session B: 12:30 p.m. – 4:00 p.m. |
Location: |
Hall E, Pennsylvania Convention Center |
Abstract: |
LB-B33 |
About CytomX Therapeutics CytomX Therapeutics
is a clinical-stage biopharmaceutical company with a deep and
differentiated oncology pipeline of Probody™ therapeutics. Probody
therapeutics exploit unique conditions of the tumor
microenvironment to more effectively localize antibody binding and
activity while limiting activity in healthy tissues. The Company’s
pipeline includes proprietary cancer immunotherapies against
clinically-validated targets, such as PD-L1 and first-in-class
Probody drug conjugates against highly attractive targets, such as
CD166 and CD71, which are considered to be inaccessible to
conventional antibody drug conjugates due to their presence on
healthy tissue. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Bristol-Myers
Squibb Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. For more information,
visit www.cytomx.com or follow us on Twitter.
Media Contact: Spectrum Amir
Khanakhan@spectrumscience.com212-899-9730
Investor Contact:Trout GroupPete
Rahmerprahmer@troutgroup.com646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Sep 2023 to Sep 2024